Return On Invested Capital
-16%
Trailing 12 months · Through 30 Jun 2026
Assumes a 21% tax rate.
Cash unavailable; invested capital does not subtract cash.
YoY relative change: -37%
Period Q2 2026 · Filed 14 Aug 2026
Return On Invested Capital
-16%
Trailing 12 months · Through 30 Jun 2026
Assumes a 21% tax rate.
Cash unavailable; invested capital does not subtract cash.
YoY relative change: -37%
Return On Equity
15%
Trailing 12 months · Through 30 Jun 2026
YoY relative change: +330%
Return On Assets
-769%
Trailing 12 months · Through 30 Jun 2026
YoY relative change: +11143%
Current Ratio
0.03x
Period-end balance · Through 30 Jun 2026
Debt-to-equity
-1.34x
Period-end balance · Through 30 Jun 2026
YoY relative change: +6.8%
NetIncomeLoss YoY
-282%
Trailing 12 months · Through 30 Jun 2026
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Invested Capital |
-16%
Trailing 12 months · 30 Jun 2026
Assumes a 21% tax rate. Cash unavailable; invested capital does not subtract cash.
|
-37% |
| Return On Equity |
15%
Trailing 12 months · 30 Jun 2026
|
+330% |
| Return On Assets |
-769%
Trailing 12 months · 30 Jun 2026
|
+11143% |
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.03x
Period-end balance · 30 Jun 2026
|
|
| Debt-to-equity |
-1.34x
Period-end balance · 30 Jun 2026
|
+6.8% |
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
-282%
Trailing 12 months · 30 Jun 2026
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
49,332,455
Period-end balance · 14 Aug 2026
|
+5.2% |
| Common Stock, Shares, Outstanding |
49,332,455
Period-end balance · 30 Jun 2026
|
+5.2% |
| Common Stock, Value, Issued |
$493,325
Period-end balance · 30 Jun 2026
|
+5.2% |
| Weighted Average Number of Shares Outstanding, Basic |
49,332,455
Reported period · 30 Jun 2026
|
+5.2% |
| Weighted Average Number of Shares Outstanding, Diluted |
49,332,455
Reported period · 30 Jun 2026
|
+3.3% |
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$77,700
Period-end balance · 30 Jun 2026
|
-60% |
| Accrued Liabilities, Current |
$37,673
Period-end balance · 30 Jun 2026
|
0% |
| Assets |
$64,687
Period-end balance · 30 Jun 2026
|
+323% |
| Assets, Current |
$64,687
Period-end balance · 30 Jun 2026
|
+323% |
| Common Stock, Par or Stated Value Per Share |
0.01
Period-end balance · 30 Jun 2026
|
0% |
| Common Stock, Shares Authorized |
100,000,000
Period-end balance · 30 Jun 2026
|
0% |
| Common Stock, Shares, Issued |
52,767,652
Period-end balance · 30 Jun 2026
|
+4.9% |
| Earnings Per Share, Basic |
0
Reported period · 30 Jun 2026
|
-100% |
| Earnings Per Share, Diluted |
0
Reported period · 30 Jun 2026
|
-100% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent |
0.21
Reported period · 30 Jun 2026
|
0% |
| General and Administrative Expense |
$120,105
Trailing 12 months · 30 Jun 2026
|
-83% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
$313,291
Trailing 12 months · 30 Jun 2026
|
-120% |
| Liabilities |
$2,097,158
Period-end balance · 30 Jun 2026
|
+5.4% |
| Liabilities and Equity |
$64,687
Period-end balance · 30 Jun 2026
|
+323% |
| Liabilities, Current |
$2,097,158
Period-end balance · 30 Jun 2026
|
|
| Nonoperating Income (Expense) |
$193,186
Trailing 12 months · 30 Jun 2026
|
-108% |
| Operating Income (Loss) |
$120,105
Trailing 12 months · 30 Jun 2026
|
+84% |
| Retained Earnings (Accumulated Deficit) |
$294,121,787
Period-end balance · 30 Jun 2026
|
-0.1% |
| Stockholders' Equity Attributable to Parent |
$2,032,471
Period-end balance · 30 Jun 2026
|
-2.9% |
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest financial period: Q2 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
14 Aug 2026
Page type
Company facts
Latest period
Q2 2026
SEC-backed company facts were refreshed from filings filed on 14 Aug 2026.
Benchmark Context
Return On Invested Capital is down about 37% versus the comparable prior period.
Compared with
Compared with NovelStem International Corp.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Invested Capital already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-08-14) highlights Return On Invested Capital -15.9%, Return On Equity 15.3%, and Return On Assets -769.1%.
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
Use these links to compare NSTM - NovelStem International Corp. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Latest value: -282%
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
8.9/100
Weak Confidence medium
-16%
Metric score 0.0/100
15%
Metric score 43.2/100
-769%
Metric score 0.0/100
No strong signals yet.
Return On Invested Capital, Return On Assets, and Current Ratio
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
CIK / security context first